Postoperative nausea and vomiting after total thyroidectomy: sevoflurane combined with prophylactic ramosetron vs. propofol-based total intravenous anesthesia

다국어 초록 (Multilingual Abstract)

Background: The frequent and distressing adverse events (AEs) of postoperative nausea and vomiting (PONV) are of major concern in 63-84% of adult patients undergoing thyroidectomy. We conducted this prospective study to compare two prophylactic strategies; sevoflurane combined with ramosetron and propofol-based total intravenous anesthesia in a homogenous group of non-smoking women undergoing total thyroidectomy.
Methods: In the current prospective study, we enrolled a consecutive series of 64 female patients aged between 20 and 65 years with an American Society of Anesthesiologists physical status of I or II who were scheduled to undergo elective total thyroidectomy under general anesthesia. Patients were randomized to either the SR (sevoflurane and remifentanil) group or the TIVA group. We evaluated the incidence and severity of PONV, the use of rescue anti-emetics and the severity of pain during the first 24 h after surgery.
Results: There were no significant differences in the proportion of the patients with a complete response and the Rhodes index, including the occurrence score, distress score and experience score, between the two groups. In addition, there were no significant differences in the proportion of the patients who were in need of rescue anti-emetics or analgesics and the VAS scores between the two groups.
Conclusions: In conclusion, TIVA and ramosetron prophylaxis reduced the expected incidence of PONV in women undergoing total thyroidectomy. In addition, there was no significant difference in the efficacy during the first 24 h postoperatively between the two prophylactic regimens.

참고문헌 (Reference)

1 Bunce KT, "The role of 5-HT in postoperative nausea and vomiting" 69 (69): S60-S62, 1992

2 이동철, "The preventative effect of ramosetron on postoperative nausea and vomiting after total thyroidectomy" 대한마취통증의학회 61 (61): 154-158, 2011

3 Cechetto DF, "The effects of propofol in the area postrema of rats" 92 : 934-942, 2001

4 Paech MJ, "The effect of anaesthetic technique on postoperative nausea and vomiting after day-case gynaecological laparoscopy" 30 : 153-159, 2002

5 Fujii Y, "The benefits and risks of different therapies in preventing postoperative nausea and vomiting in patients undergoing thyroid surgery" 3 : 27-34, 2008

6 Rhodes VA, "The Index of Nausea, Vomiting, and Retching: a new format of the Index of Nausea and Vomiting" 26 : 889-894, 1999

7 Gan TJ, "Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting" 105 : 1615-1628, 2007

8 White H, "Randomized comparison of two anti-emetic strategies in high-risk patients undergoing day-case gynaecological surgery" 98 : 470-476, 2007

9 Ryu J, "Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy" 24 : 812-817, 2010

10 Kang YK, "Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron" 30 : 220-229, 2002

11 Brooker CD, "Propofol manitenance to reduce postoperative emesis in thyroidectomy patients: a group sequential comparison with isoflurane/nitrous oxide" 26 : 625-629, 1998

12 Jost U, "Propofol and postoperative nausea and/or vomiting" 46 : 776-782, 1997

13 Kim SI, "Prevention of postoperative nausea and vomiting by continuous infusion of subhypnotic propofol in female patients receiving intravenous patient-controlled analgesia" 85 : 898-900, 2000

14 Golembiewski J, "Prevention and treatment of postoperative nausea and vomiting" 62 : 1247-1260, 2005

15 Lee HJ, "Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients" 25 : 756-762, 2008

16 Watcha MF, "Postoperative nausea and vomiting" 77 : 162-184, 1992

17 Marsh B, "Pharmacokinetic model driven infusion of propofol in children" 67 : 41-48, 1991

18 Sonner JM, "Nausea and vomiting following thyroid and parathyroid surgery" 9 : 398-402, 1997

19 Laxenaire MC, "Life threatening anaphylactoid reactions to propofol" 77 : 275-280, 1992

20 Minto CF, "Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development" 86 : 10-23, 1997

21 Song YK, "Effects of ramosetron and dexamethasone on postoperative nausea, vomiting, pain, and shivering in female patients undergoing thyroid surgery" 27 : 29-34, 2013

22 Hill RP, "Cost-effectiveness of prophylactic antiemetic therapy ith ondansetron, droperidol, or placebo" 92 : 958-967, 2000

23 Apfel CC, "Comparison of surgical site and patient’s history with a simplified risk score for the prediction of postoperative nausea and vomiting" 59 : 1078-1082, 2004

24 Kim SI, "Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery" 103 : 549-553, 2009

25 Ewalenko P, "Antiemetic effect of subhypnotic doses of propofol after thyroidectomy" 77 : 463-467, 1996

26 Sneyd JR, "A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents" 15 : 433-445, 1998

27 Etchu H, "A case of convulsion induced by propofol" 47 : 77-78, 1998

28 Park SK, "A Randomized controlled trial of two different interventions for the prevention of postoperative nausea and vomiting: total intravenous anaesthesia using propofol and remifentanil versus prophylactic palonosetron with inhalational anaesthesia using sevofluranenitrous oxide" 39 : 1808-1815, 2011